KR101917920B1 - Preparation Method of Stable Fucoxanthin Nanoliposome And Cosmetic Composition Comprising The Same - Google Patents
Preparation Method of Stable Fucoxanthin Nanoliposome And Cosmetic Composition Comprising The Same Download PDFInfo
- Publication number
- KR101917920B1 KR101917920B1 KR1020160023131A KR20160023131A KR101917920B1 KR 101917920 B1 KR101917920 B1 KR 101917920B1 KR 1020160023131 A KR1020160023131 A KR 1020160023131A KR 20160023131 A KR20160023131 A KR 20160023131A KR 101917920 B1 KR101917920 B1 KR 101917920B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- solution
- nanoliposome
- fucoxanthin
- cosmetic composition
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to a method for producing a microorganism which comprises adding a first solution of fucoxanthin dissolved in a solubilization solution containing ethanol, lecithin, cholesterol, butylated hydroxytoluene and tocopheryl acetate to ionized water to obtain a second solution, Thereby producing nanoparticles of stabilized fucosanthin and a cosmetic composition containing the nanoliposome particles produced by the method.
Description
The present invention relates to a method for producing nano-liposome particles of stabilized fucosanthin and a cosmetic composition containing the nanoliposome particles prepared by the method. More particularly, the present invention relates to a cosmetic composition containing nano-liposome particles, A method for producing a stabilized fucosanthin nanoliposome particle which can be provided as a functional material for a high value added product by keeping the titer for a long period of time even under room temperature and refrigeration conditions, The present invention relates to a cosmetic composition containing nano liposome particles.
Recently, research has been reported that the ingredients contained in seaweeds are beneficial to human health. Particularly, it is known that fucosanthin is a specific carotenoid found abundantly in brown algae, has an anti-obesity effect and has been reported to have skin whitening or wrinkle-reducing activity and can be provided as a material for functional products such as cosmetics Only.
It is also known that fucoxanthin can be obtained by extraction and purification from a conventional brown algae by an acetone extraction method or a hexane extraction method. The fucosanthin thus extracted has low stability under room temperature and refrigeration conditions, It is difficult to apply fucosanthin alone to the production of other functional products including cosmetics due to difficult problems.
Accordingly, the present inventors have devised a solution to the above-mentioned problem, and the object of the present invention is to provide a folic acid / fucosanthin derivative which is stabilized by nanoliposomalization of fucosanthin to be added to the food or cosmetic composition as an active ingredient, The present invention also provides a method for producing a stabilized fucosanthin nanoparticle particle which can be provided as a functional material for a high value-added product.
Another object of the present invention is to provide a cosmetic composition for skin whitening and wrinkle improvement wherein the fucoxanthin is formulated into nanoliposome particles as described above and stabilized and added as a functional material of cosmetics.
The technical problem of the present invention as described above is achieved by the following means.
(1) A first solution obtained by dissolving fucoxanthin in a solubilization solution containing ethanol, lecithin, cholesterol, butylated hydroxytoluene, and tocopheryl acetate is added to ionized water to obtain a second solution, And a step of pressurizing with a fluoridizer to produce nanoparticles.
(2) In the above (1)
A solubilization solution containing 1 to 5% by weight of lecithin, 0.5 to 5% by weight of cholesterol, 0.05 to 0.1% by weight of butylated hydroxytoluene and 0.05 to 0.1% by weight of tocopheryl acetate, based on the weight of the first solution, 40 to 60% by weight of a first solution in which fucoxanthin is dissolved in an amount of 10 to 100 ppm based on the total weight of the second solution is heated to 60 to 70 캜 and the warmed first solution is heated to 60 to 70 캜 To 40 to 60 wt% of ionized water to obtain a second solution, and pressurizing the second solution with a microfluidizer to prepare nanoparticles.
(3) In the above (2)
0.05 to 0.5% by weight of ammonium acryl dimethyltaurate based on the weight of the second solution and 0.05 to 0.5% by weight of the methacrylate polymer based on the weight of the second solution are added to the second solution ≪ / RTI > wherein the stabilized fucosanthin is a fucosanthin.
(4) In the above (2)
And adding 1.0 to 5.0% by weight of titanium oxide to the second solution. ≪ RTI ID = 0.0 > 11. < / RTI >
(5) A cosmetic composition for skin whitening and wrinkle improvement containing nanoliposome particles produced by any one of the methods (1) to (4).
As described above, according to the present invention, stabilization of fucosanthin by nanoliposomes can maintain the titer for a long period of time even under room temperature and refrigeration conditions, and can provide stabilized fucosanthin nanoliposome Particles and a cosmetic composition for improving skin whitening and wrinkles containing the same as a functional material.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a flow chart for the preparation of stabilized fucosanthin nanoliposome particles according to the present invention.
In order to accomplish the above object, the present invention provides a method for preparing a stabilized fucosanthin nanoliposome particle, which comprises dissolving fucoxanthin in a solubilization solution containing lecithin, cholesterol, butylated hydroxytoluene, and tocopheryl acetate in ethanol Adding a first solution to ionized water to obtain a second solution, and pressurizing the second solution with a microfluidizer to prepare nanoparticles.
Hereinafter, the contents of the present invention will be described in more detail.
In the present invention, to stabilize fucoxanthin, lecithin and cholesterol are added to ethanol to solubilize fucoxanthin, and butylated hydroxytoluene and tocopheryl acetate are added to the ethanol solution to promote stabilization, and a first solution .
For the solubilization of fucoxanthin, lecithin is added in an amount of 1 to 5% by weight, preferably 1 to 2% by weight, most preferably 1.5% by weight, based on the weight of the first solution, 0.5 to 5% by weight, preferably 0.5 to 0.6% by weight, most preferably 0.5% by weight, based on the total weight of the composition.
In the present invention, butylated hydroxytoluene is added in an amount of 0.05 to 0.1% by weight, preferably 0.05 to 0.06% by weight, and most preferably 0.05% by weight, based on the weight of the first solution, And tocopheryl acetate are added in an amount of 0.05 to 0.1% by weight, preferably 0.05 to 0.06% by weight, most preferably 0.05% by weight, based on the weight of the first solution.
In the present invention, the solubilization solution containing 1 to 5% by weight of lecithin, 0.5 to 5% by weight of cholesterol, 0.05 to 0.1% by weight of butylated hydroxytoluene and 0.05 to 0.1% by weight of tocopheryl acetate, 40 to 60% by weight (based on the weight of the final solution) of the first solution obtained by dissolving xanthan gum in a predetermined amount is heated to 60 to 70 캜, and the warmed first solution is heated to 60 to 70 캜 to 40 to 60% To prepare a second solution.
More preferably, ammonium acryl dimethyltaurate is added in an amount of 0.05 to 0.5% by weight based on the weight of the second solution and the methacrylate polymer is added to the second solution in an amount of 0.05 to 0.5% by weight based on the weight of the second solution Thereby improving the dispersibility of the nanoliposome and at the same time obtaining more stabilized nanoliposome in heat and light.
Preferably, 1.0 to 5.0% by weight of titanium oxide is further added to impart more stability to light. The titanium oxide can improve the stability by binding to the nanoliposome and providing an effect of scattering ultraviolet rays.
At this time, it is preferable to add the fucoxanthin in an amount of 10 to 1000 ppm based on the total weight of the second solution.
The reaction solution prepared as described above is nanoized using a microfludizer. Microfluidizer is Immobilizer (Microfludizer) is a commercially available device (for example, Material Microfluidizer Processor ®), and may be used, it is sufficient to prepare a nano-liposomes according to the conventional method.
The nanoliposome containing fucoxanthin obtained through the above process is utilized as a functional material for skin whitening or wrinkle improving cosmetic.
In the cosmetic composition according to the present invention, the nanoliposome containing fucoxanthin obtained according to the above method is preferably added in an amount of 0.1 to 5.0% by weight based on the total weight of the cosmetic composition, whitening activity, The effect of improving wrinkles is further strengthened.
The cosmetic composition according to the present invention may contain components commonly used in cosmetics, and includes conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers.
The cosmetic composition of the present invention may be prepared in any form conventionally produced in the art and may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant- , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be manufactured in the form of a flexible lotion, a convergent lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
Hereinafter, the present invention will be described in more detail with reference to examples. However, these embodiments are for the purpose of understanding the present invention and should not be construed as limiting the scope of the present invention.
[Example 1]
To the solubilized solution containing 1.5% by weight of lecithin, 0.5% by weight of cholesterol, 0.05% by weight of butylated hydroxytoluene and 0.05% by weight of tocopheryl acetate was added to ethanol, fucosanthin (adjusted to 10 ppm based on the total weight of the second solution ) Was heated to 70 DEG C and the warmed first solution was added to 50 wt% of ionized water heated to 70 DEG C to obtain a second solution, and then the second solution was added to microfluid The fucosantin nanoliposome particles were prepared by using a laser.
[Example 2]
Fucosanthin nanoliposome particles were prepared by the same procedure as in Example 1 except that 0.5% by weight of ammonium acryl dimethyltaurate and 0.3% by weight of methacrylate polymer were added to the second solution.
[Example 3]
The nanoliposome particle of fucosanthin was prepared by the same procedure as in Example 2 except that 1.0 wt% of titanium oxide was added to the second solution.
[Production Example 1, 2, 3] Preparation of cream
Preparation Examples 1, 2 and 3 and Comparative Example 1 were prepared with the compositions shown in Table 1 below.
[Production Examples 4, 5 and 6] Production of Lotion
Production Examples 4, 5 and 6 and Comparative Example 2 were prepared with the compositions shown in Table 2 below.
[Experimental Example 1] Stability evaluation
As a result of evaluating the stability of fucoxanthin in the samples prepared in Examples 1 to 3 for 12 weeks, the results of Examples 1 to 3 are shown in Table 3 under room temperature, refrigerated storage condition (4 ° C) It can be confirmed that it is superior to the comparative example (using only fucozanthin itself, which is not a nanoliposome structure, but having the same concentration), which is superior to the case of Examples 2 and 3. It can be confirmed that the stability in the case of Example 3 was improved especially under daylight conditions.
♪: Relative content (%)
[Experimental Example 2] Confirmation of inhibition of pigment deposition
Experiments were carried out in the following manner to verify the inhibitory effects of the cosmetic samples prepared in Preparation Examples 1 to 3 on pigmentation.
Twenty healthy subjects were selected and aluminum foil having a diameter of 7 mm and having a diameter of 7 mm and having two lines was attached to the lower part of both arms. Using an ORIEL solar simulator 1000 W at a distance of 10 cm from the arm, / cm < 2 > Before irradiation, the irradiated sites were washed well with 70% aqueous ethanol solution. Preparation Examples 1 to 3 and Comparative Example 1 were applied to the same row three days before irradiation and two times a day until eight weeks after irradiation.
The determination of the whitening effect was made by visually determining the degree of pigmentation of the production examples and the comparative examples for each of them, and the degree of inhibition of pigment deposition compared with the formulation of the comparative example was markedly improved, And the results are shown in Table 4 below.
As shown in Table 4, the cosmetic preparations of Preparation Examples containing the substances of the present invention showed excellent skin whitening effect as compared to Comparative Example 1 which is a common cosmetic.
[Experimental Example 3] Wrinkle-improving effect test
The wrinkle-improving effect can be generally measured by the effect of collagen biosynthesis performance and collagenase degradation inhibition ability. For this purpose, human normal fibroblast was inoculated into a 6-well microplate containing DMEM medium (2 x 10 5 cells / well) and cultured in a 5% CO 2 incubator at 37 ° C for 24 hours . After 24 hours, the medium was removed from each well and the samples of Examples 1 to 3 were each treated and then re-cultured for 24 hours. After 24 hours, the cell culture medium was collected to prepare a sample. The amount of collagen synthesis was measured by using a procollagen type I C-peptide (type I C-peptide) in a cell culture medium using a collagen measurement kit (Procollagen type I C-peptide EIA kit (MK101), Takara, : PICP) was measured and analyzed. An antibody against collagenase was used as a method for measuring the activity of collagenase degrading collagen. The collagenase activity was measured using a Type I collagenase assay kit (Amersham Biosciences, RPN2629) and the absorbance was measured with an ELISA reader. The measured values were expressed as mean ± standard deviation, and the significance was tested by t-test using the SPSS / PC + program. The results are shown in Table 5 below.
As shown in Table 5, the nanoliposomes according to the present invention all increased collagen synthesis and inhibited collagenase activity.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention as defined in the appended claims. It can be understood that
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160023131A KR101917920B1 (en) | 2016-02-26 | 2016-02-26 | Preparation Method of Stable Fucoxanthin Nanoliposome And Cosmetic Composition Comprising The Same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160023131A KR101917920B1 (en) | 2016-02-26 | 2016-02-26 | Preparation Method of Stable Fucoxanthin Nanoliposome And Cosmetic Composition Comprising The Same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170100804A KR20170100804A (en) | 2017-09-05 |
KR101917920B1 true KR101917920B1 (en) | 2018-11-13 |
Family
ID=59924598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160023131A KR101917920B1 (en) | 2016-02-26 | 2016-02-26 | Preparation Method of Stable Fucoxanthin Nanoliposome And Cosmetic Composition Comprising The Same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101917920B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109805388A (en) * | 2019-01-25 | 2019-05-28 | 集美大学 | A kind of fucoxanthol-oyster peptide nanoparticles and its preparation method and application |
-
2016
- 2016-02-26 KR KR1020160023131A patent/KR101917920B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20170100804A (en) | 2017-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20180032479A (en) | Nano Liposome Composition Comprising Peptide for Easy Penetrating into Skin | |
KR101410632B1 (en) | Cosmetic Composition Comprising Fucoxanthin Derived from Microalgae and The Preparation Method thereof | |
CH697417B1 (en) | Agents for the treatment of skin aging comprising paeoniflorin. | |
KR100501399B1 (en) | Cosmetic Compostion for Preventing Skin Aging Comprising Plant Extract as Oriental Medicine Stabilized in Nanoliposome | |
US5849309A (en) | Skin activator with glycosaminoglycan production-accelerating effect | |
KR101425708B1 (en) | Preparation method of cosmetic composition comprising saponin from sea slug and the cosmetic composition thereby | |
KR20150122869A (en) | Cosmetic composition for near infrared ray block and near infrared ray blocker | |
JP3619185B2 (en) | Cosmetics | |
KR20140033815A (en) | Derivatives of quinic acid and the use thereof | |
KR101917920B1 (en) | Preparation Method of Stable Fucoxanthin Nanoliposome And Cosmetic Composition Comprising The Same | |
KR101862231B1 (en) | Cosmetic composition for preventing near infrared ray containing extract of ganoderma lucidum | |
JP2008094792A (en) | Hyaluronic acid synthesis promoter, anti-aging agent and skin care preparation each containing commelina communis var. hortensis-derived flavonoid | |
JP4167247B2 (en) | Skin preparation | |
KR101855465B1 (en) | Preparation Method of Stable Fucoxanthin Microcapsule And Cosmetic Composition Comprising The Same | |
KR101535327B1 (en) | Emulsion Cosmetic Composition Having Liquid Crystal Structure | |
KR101776140B1 (en) | Cosmetic composition for near infrared ray block and near infrared ray blocker | |
JP2010150173A (en) | Skin whitening agent, melanogenesis inhibitor, and skin whitening skin external preparation | |
JP2010018559A (en) | Cosmetic composition containing biosurfactant | |
JP2009242310A (en) | Involucrin production promoter, transglutaminase-1 production promoter, e-cadherin production promoter and skin care preparation for external use for making skin pore inconspicuous | |
JP5000964B2 (en) | Testosterone 5α-reductase activity inhibitor, androgen receptor antagonist, use thereof, and method for suppressing androgen activity expression | |
KR101139686B1 (en) | A cosmetic composition comprising bittern | |
JP2009084243A (en) | Horny layer hyaluronic acid production accelerator and external dermatological preparation, cosmetic, and quasi-drug containing horny layer hyaluronic acid production accelerator | |
KR20150057737A (en) | Whitening cosmetics composition | |
JP2007176832A (en) | Skin ageing-preventing composition containing extract of aphanizomenon | |
JP2015221756A (en) | Yeast culture and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |